{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:32Z","timestamp":1792685972727,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a heterogeneous disease with a clinical presentation that varies according to geographical area and TTR mutation. The symptoms of Val50Met-ATTRv are mainly neuropathic and progress to complete disability and death in most untreated patients within 10 to 15\u00a0years of diagnosis. The neurological effects may also be accompanied by gastrointestinal impairment, cardiomyopathy, nephropathy and\/or ocular deposition. The disease is thus associated with a high degree of patient disability. Accordingly, we aimed to describe the psychosocial burden associated with ATTRv in a group of patients, asymptomatic Val50Met carriers, relatives and caregivers in the endemic focus of the disease in Majorca via a survey addressing various aspects related to psychosocial burden. We performed a an observational, descriptive, cross-sectional and multicentre study in order to analyze the prevalence of self-reported impact of ATTRv disease upon their daily life. In addition to the self-knowledge, fear and burden related to the disease. The survey was disseminated during the regular follow up at the outpatient clinic of the Hospital Universitario Son Ll\u00e0tzer and during the meetings organized by the Andrade\u2019s Disease patients\u2019 advocacy group from the Balearic Islands. These meetings were attended also by subjects followed up by the Hospital Universitario Son Espases and their caregivers and relatives. Survey was self-administrated. No intervention was done by the investigators. 85 subjects completed the survey: 61 carrying the TTR-V50M variant and 24 caregivers or relatives.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study revealed that, although most of the population studied had had prior contact with ATTRv through affected relatives, there was still a lack of information regarding disease diagnosis. Fear of the genetic test result and psychological issues were common in our population. Moreover, the disease had a stronger impact on the daily life of our patients than that of our asymptomatic carriers. Autonomic symptoms were the main source of burden for relatives and caregivers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our survey results show high psychosocial burden associated with Val50Met-ATTRv in our area.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01910-5","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:07:40Z","timestamp":1623312460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden"],"prefix":"10.1186","volume":"16","author":[{"given":"Juan","family":"Gonz\u00e1lez-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Gaya-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Losada-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bosch-Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Ripoll-Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Us\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Figuerola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Descals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Montal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Ferrer-Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4109-4635","authenticated-orcid":false,"given":"Eugenia","family":"Cisneros-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"1910_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plant\u00e9-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1910_CR2","first-page":"160","volume":"10","author":"LH Connors","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2003;10(3):160\u201384.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"1","key":"1910_CR3","first-page":"54","volume":"12","author":"M Munar-Qu\u00e9s","year":"2005","unstructured":"Munar-Qu\u00e9s M, Saraiva MJ, Viader-Farr\u00e9 C, Zabay-Becerril JM, Mulet-Ferrer J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2005;12(1):54\u201361.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"3","key":"1910_CR4","first-page":"31","volume":"30","author":"M Raya-Cruz","year":"2015","unstructured":"Raya-Cruz M, Buades-Reines J, Gallego-Lez\u00e1un C, Ripoll-Vera T, Us\u00f3n-Mart\u00edn M. Clinical and analytical variability in cases of familial amyloidotic polyneuropathy (PAF-TTR): comparison between healthy carriers and symptomatic patients. Med Balear. 2015;30(3):31\u20136.","journal-title":"Med Balear"},{"key":"1910_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2047-9158-3-19","volume":"3","author":"M Ueda","year":"2014","unstructured":"Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.","journal-title":"Transl Neurodegener"},{"issue":"2","key":"1910_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1529-8027.2011.00331.x","volume":"16","author":"M Cappellari","year":"2011","unstructured":"Cappellari M, Cavallaro T, Ferrarini M, Cabrini I, Taioli F, Ferrari S, Merlini G, Obici L, Briani C, Fabrizi GM. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst JPNS. 2011;16(2):119\u201329.","journal-title":"J Peripher Nerv Syst JPNS"},{"issue":"2","key":"1910_CR7","first-page":"53","volume":"18","author":"H Koike","year":"2011","unstructured":"Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2011;18(2):53\u201362.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"7","key":"1910_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","volume":"69","author":"V Plant\u00e9-Bordeneuve","year":"2007","unstructured":"Plant\u00e9-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693\u20138.","journal-title":"Neurology"},{"issue":"12","key":"1910_CR9","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","volume":"260","author":"MF Dohrn","year":"2013","unstructured":"Dohrn MF, R\u00f6cken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, Ferbert A, Hinderhofer K, Schr\u00f6der JM, Weis J, Schulz JB, Claeys KG. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013;260(12):3093\u2013108.","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"1910_CR10","first-page":"61","volume":"19","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, Signate A, Vial C, Maisonobe T, Delmont E, Franques J, Vallat JM, Sole G, Pereon Y, Lacour A, Echaniz-Laguna A, Misrahi M, Lacroix C, French Network for FAP. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2012;19(Suppl 1):61\u20134.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"Suppl 1","key":"1910_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","volume":"29","author":"Y Parman","year":"2016","unstructured":"Parman Y, Adams D, Obici L, Gal\u00e1n L, Guergueltcheva V, Suhr OB, Coelho T, European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3\u201313.","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"1910_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086\u201397.","journal-title":"Lancet Neurol"},{"key":"1910_CR13","first-page":"139","volume":"5","author":"A Lopes","year":"2003","unstructured":"Lopes A. Depress\u00e3o em PL: Aspectos ligados \u00e0s doen\u00e7as gen\u00e9ticas de in\u00edcio tardio. Revista Portuguesa de Psicossom\u00e1tica. 2003;5:139\u201344.","journal-title":"Revista Portuguesa de Psicossom\u00e1tica"},{"issue":"11","key":"1910_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1001\/archpsyc.1988.01800350021003","volume":"45","author":"A Breier","year":"1988","unstructured":"Breier A, Kelsoe JR Jr, Kirwin PD, Beller SA, Wolkowitz OM, Pickar D. Early parental loss and development of adult psychopathology. Arch Gen Psychiatry. 1988;45(11):987\u201393.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1910_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12687-017-0338-0","volume":"9","author":"A Lopes","year":"2018","unstructured":"Lopes A, Sousa A, Fonseca I, Branco M, Rodrigues C, Coelho T, Sequeiros J, Freitas P. Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study. J Community Genet. 2018;9(1):93\u20139.","journal-title":"J Community Genet"},{"issue":"5","key":"1910_CR16","first-page":"3676","volume":"55","author":"M Alves-Ferreira","year":"2018","unstructured":"Alves-Ferreira M, Coelho T, Santos D, et al. A trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30M in Portugal. Mol Neurobiol. 2018;55(5):3676\u201383.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"1910_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1468-1331.2008.02429.x","volume":"16","author":"MA Saporta","year":"2009","unstructured":"Saporta MA, Zaros C, Cruz MW, et al. Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families. Eur J Neurol. 2009;16(3):337\u201341.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1910_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pelli\u00e9 C, Plant\u00e9-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15(3):181\u20136.","journal-title":"Amyloid"},{"issue":"3","key":"1910_CR19","first-page":"249","volume":"52","author":"S Fassino","year":"2010","unstructured":"Fassino S. Psychosomatic approach is the new medicine tailored for patient personality with a focus on ethics, economy, and quality. Panminerva Med. 2010;52(3):249\u201364.","journal-title":"Panminerva Med"},{"issue":"Suppl 1","key":"1910_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10286-019-00624-w","volume":"29","author":"T Gendre","year":"2019","unstructured":"Gendre T, Plant\u00e9-Bordeneuve V. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy. Clin Auton Res. 2019;29(Suppl 1):25\u201331.","journal-title":"Clin Auton Res"},{"issue":"2","key":"1910_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","volume":"29","author":"A Gonzalez-Duarte","year":"2019","unstructured":"Gonzalez-Duarte A. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis). Clin Auton Res. 2019;29(2):245\u201351.","journal-title":"Clin Auton Res"},{"issue":"3","key":"1910_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","volume":"267","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte A, Berk JL, Quan D, et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis [published correction appears in J Neurol. 2020 Feb 7]. J Neurol. 2020;267(3):703\u201312.","journal-title":"J Neurol"},{"issue":"4","key":"1910_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1526924818800033","volume":"28","author":"MT Tom\u00e1s","year":"2018","unstructured":"Tom\u00e1s MT, Melo X, Mateus \u00c9, Gon\u00e7alves M, Barroso E, Santa-Clara H. A 5-year follow-up of the benefits of an exercise training program in liver recipients transplanted due to familial amyloidotic polyneuropathy. Prog Transplant. 2018;28(4):330\u20137.","journal-title":"Prog Transplant"},{"issue":"1","key":"1910_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-019-1199-x","volume":"14","author":"MP Connolly","year":"2019","unstructured":"Connolly MP, Panda S, Patris J, Hazenberg B. Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2019;14(1):220. https:\/\/doi.org\/10.1186\/s13023-019-1199-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"1910_CR25","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T, European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29(Suppl 1):S27\u201335.","journal-title":"Curr Opin Neurol"},{"key":"1910_CR26","doi-asserted-by":"publisher","unstructured":"Losada I, Gonz\u00e1lez-Moreno J, Rodriguez A, et al. Multidisciplinary approach in the management of hATTR. Eur J Clin Investig 2020;50:e13296. https:\/\/doi.org\/10.1111\/eci.13296.","DOI":"10.1111\/eci.13296"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01910-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01910-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:10:10Z","timestamp":1623312610000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01910-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1910"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01910-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, identified as IB3463\/17, was approved by the Ethics Committee of the Balearic Islands prior to the initiation of the recruitment period. All participants included in the study agreed to participate by signing an informed consent form before being provided the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors hold financial interests in the sponsoring organisation. The results described here do not contain any product specific names or literature from the sponsoring company. The authors declare no competing interests in relation to the work described here.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}